CCLG statement: Outcome after high-risk neuroblastoma treatment
SIOPEN, the UK National Cancer Research Institute Neuroblastoma Group and the CCLG Neuroblastoma Special Interest Group are committed to further improving the outcome for children with neuroblastoma.
BEACON study opens in Europe
This new clinical trial will be available to children in 40 hospitals across 11 European countries and has been jointly funded by Solving Kids’ Cancer UK and the French charity, Imagine for Margo.
Solving Kids' CancerUK receives £21,114 from GamesAid
Solving Kids' Cancer UK thanks GamesAid – the UK video games industry based charity – for their important and generous support in 2019.
Solving Kids’ Cancer UK grant to Professor John Anderson
Solving Kids’ Cancer is pleased to announce that it has awarded a grant of £250,000 to Professor John Anderson of UCL, to study preclinical refinements of treatment of neuroblastoma with CAR-T cells.
Investigating clinical and biological factors associated with relapse
A team at Newcastle University are carrying out a neuroblastoma study that is being sponsored by Newcastle upon Tyne Hospitals NHS Trust and funded by Action Medical Research.
Solving Kids’ Cancer UK comment on NHS England’s Long Term Plan
We are pleased to see many of our own aims included in the new NHS England Long Term Plan, areas we are working so hard on to improve outcomes for children and families affected by neuroblastoma.
Solving Kids' Cancer UK response to melatonin media coverage
On Friday 14 September and over the weekend that followed, a social media post and related media coverage from the charity Children with Cancer UK called for the supplement melatonin to be made available to children and young people with cancer on the NHS
Joint statement in response to NICE’s decision to approve anti-GD2 antibody therapy dinutuximab beta
Families now know their very sick child will be able to have the best treatment that gives the greatest chance of long-term survival here in the UK.
Anti-GD2 antibody therapy update, May 2018
Following the recent provisional decision by the National Institute for Health and Care Excellence (NICE) not to approve dinutuximab beta (Qarziba™) for use on the NHS in England and Wales, we have updated our briefing document.
